Across TCGA pan-cancer cohorts, ANKRD45 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANKRD45 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ANKRD45 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKRD45 expression acts as an unfavorable survival marker.
BLCA, SARC, and UCEC are the cancer types where ANKRD45 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.